Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Share-based Compensation (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Share-based Compensation data on record, last reported at $4.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 7.28% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $19.6 million, up 9.46%, while the annual FY2025 figure was $19.6 million, 9.46% up from the prior year.
  • Share-based Compensation reached $4.4 million in Q4 2025 per TRDA's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.1 million in Q3 2025 and bottomed at $1.8 million in Q1 2022.
  • Average Share-based Compensation over 4 years is $3.8 million, with a median of $3.8 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 53.57% in 2023, then dropped 7.28% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $2.9 million in 2022, then soared by 33.28% to $3.8 million in 2023, then grew by 22.36% to $4.7 million in 2024, then dropped by 7.28% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $4.4 million in Q4 2025, $5.1 million in Q3 2025, and $5.0 million in Q2 2025.